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Leishmaniasisisaneglecteddiseaseresultinginaglobalmorbidityof2,090thousandDisability-AdjustedLifeYearsandamortality
rate of approximately 60,000 per year. Among the three clinical forms of leishmaniasis (cutaneous, mucosal, and visceral), visceral
leishmaniasis (VL) accounts for the majority of mortality, as if left untreated VL is almost always fatal. Caused by infection with
Leishmania donovani or L. infantum, VL represents a serious public health problem in endemic regions and is rapidly emerging as
an opportunistic infection in HIV patients. To date, no vaccine exists for VL or any other form of leishmaniasis. In endemic areas,
the majority of those infected do not develop clinical symptoms and past infection leads to robust immunity against reinfection.
ThusthedevelopmentofvaccineforLeishmaniaisarealisticpublichealthgoal,andthispapersummarizesadvancesinvaccination
strategies against VL.
1.Introduction
There is currently no vaccine available for any form of
leishmanias, including visceral leishmaniasis (VL), which if
left untreated is almost always fatal. VL results from systemic
infection with L. infantum (also known as L. chagasi)[ 1]
which occurs in Europe, North Africa, South and Central
America, and L. donovani, which is found throughout East
Africa, India, and parts of the Middle East. Infection is
initiated by the bite of an infected sand ﬂy vector and
parasites disseminate from the site of infection in the skin
to reside and multiply within macrophages of the liver,
spleen, and bone marrow [2]. VL, also known as kala-zar, is
associated with fever, weight loss, enlargement of the spleen
and liver, and anaemia. Leishmaniasis has strong links with
poverty [3] and is considered one of the most neglected
tropical diseases. Each year there are approximately 500,000
new cases of VL with over 90% of cases arising in India,
Bangladesh, Nepal, Sudan, and Brazil. VL has become a
frequent coinfection in HIV-positive individuals in endemic
areas and is associated with enhanced onset of AIDS-related
illness and increased VL treatment failure. Current VL
therapy is based on the long-term parenteral administration
of pentavalent antimonials, which, despite being expensive
and highly toxic, has been the standard treatment for over
50years.
Following L. donovani infection some individuals
develop Post-kala-azar Dermal Leishmaniasis (PKDL), a
complication that occurs either during or after treatment.
During PKDL parasites reappear in the skin resulting in an
array of small skin lesions, and patients are considered a
signiﬁcant infection reservoir because of the large number of
parasites accessible to sand ﬂy bites. Thus the treatment and
control of PKDL are an important public health measure for
controlling VL and must be considered in the development
of VL vaccine strategies.
Host resistance to Leishmania infection is mediated by
cellular immune responses leading to macrophage activation
and parasite killing. Antileishmanial immunity is mediated
by both innate and adaptive immune responses and requires
eﬀective activation of macrophages, dendritic cells (DCs),
and antigen-speciﬁc CD4+ and CD8+ T cells [4]. Although
strong humoral responses are induced by VL infection,
antibodies play no role in protection and are often associated
with disease exacerbation [5]. Eﬀector CD4+ T cells are
responsible for the production of cytokines critical for the
activation of macrophages and are required for optimal host
response to infection [6]. Cytotoxic CD8+ T cells also play2 Journal of Tropical Medicine
a host protective role, and are required for the eﬀective
clearance of parasites [7] and the generation of memory
responses [8]. Interestingly, 80 to 90% of human infections
are subclinical or asymptomatic, and this asymptomatic
infection is associated with strong cell-mediated immunity.
Only a small percentage of infected individuals develop
severe disease, and patients who recover from VL display
resistance to reinfection. This suggests the development of
clinical immunity and provides a biological rationale for the
development of VL vaccines that impart a strong cellular
immunity.
Humans are the only known hosts for L. donovani;
however L. infantum is primarily a zoonotic disease and
canine species are the main animal reservoir. Canine visceral
leishmaniaisis (CVL) aﬀectsmillions of dogs in Europe, Asia,
North Africa, and South America and has been associated
with outbreaks of human VL [9]. Both symptomatic and
asymptomatic Leishmania-infected dogs act as a source of
parasites for VL transmission [10], and CVL represents
a signiﬁcant public health issue. A current approach to
breaking the VL transmission cycle is the development of
CVL vaccine, which may be crucial for controlling VL
infection in human populations.
Vaccination against VL has received limited attention
compared with cutaneous leishmaniasis (CL). Historically
CL has been the focus of vaccination attempts, as it has
been known for centuries that people who resolve a primary
CL skin lesion are protected from further infections. It is
generally acknowledged that human VL trials will follow on
from any successful CL immunization programme. Ideally
a vaccine would provide cross-protection against multiple
Leishmaniaspecies.Therecentcomparativegenomicanalysis
of three Leishmania species, which cause distinct disease
pathologies, showed that L. major, L. braziliensis, and L.
infantum genomes are highly conserved and have very
few species-speciﬁc genes [11]. The level of amino acid
conservation within coding regions is also high between
species, suggesting that the major Leishmania antigens are
conserved and that a pan species vaccine may be achievable.
However there is a high degree of variability in the cross-
protective immunity induced by infection with diﬀerent
Leishmania species [12, 13] and VL-speciﬁc vaccines may
provide a more successful intervention.
Experimental infection models are used to screen and
evaluate VL vaccines, and several animal species have been
used including mice, hamsters, monkeys, and dogs [14].
However no single in vivo model accurately reﬂects all
aspects of human VL disease, which has been a major
limitation in the development of VL vaccines. The precise
immunemechanismsunderlyinghumanVLarestillnotfully
understood, and the responses necessary for protection by
vaccination in experimental infection models may not reﬂect
those required for eﬃcacy in endemic areas [15].
The proﬁle of an antileishmanial vaccine would need to
i n c o r p o r a t es e v e r a li m p o rt a n tf e a t u r e s ,s u c ha ss a f e t y ,e a s eo f
production at a low cost in endemic countries, the induction
of robust, long-term T cell responses, and both prophylactic
and therapeutic eﬃcacy. Ideally, such vaccine would oﬀer
cross-species eﬀectiveness against CL and VL. As this might
not be feasible, the development of a VL-speciﬁc vaccine
remains an important global health priority.
2. First-GenerationVaccines
The only successful intervention against leishmaniasis is
inoculation using virulent parasites, a process known as
leishmanization (LZ). This ancient practise involves the
administration of cutaneous Leishmania parasites to a dis-
crete skin location, allowing a self-healing lesion to form.
Initial immunological exposure then protects the individual
from further infection and lesion development. LZ was
traditionally practised by directly transferring infectious
material from cutaneous lesions to uninfected individuals.
However the establishment of an in vitro culture system in
the early 20th century led to the large-scale production of
promastigote forms of Leishmania for expanded clinical use.
LZ induces a controlled, but full, infection and was success-
fully used as a prophylaxis throughout the Soviet Union,
Asia, and the Middle East, with reported eﬃcacy levels up
to 100% [16, 17]. However LZ was largely abandoned due
to safety issues associated with the use of live vaccines. Also,
standardisation of the inoculum proved diﬃcult as parasites
used for LZ experience a dramatic loss of infectivity when
subject to repeated subculturing [18]. Infection with live
Leishmania also causes immunosuppression, which resulted
in reduced immune responses to childhood vaccines and
threatened the eﬃcacy of immunization programmes [19,
20]. Currently only one country, Uzbekistan, employs the
use of LZ, where a mixture of live and dead L. major is
licensed as a vaccine for high-risk populations [21]. As LZ
is the only vaccine strategy against Leishmania with proven
eﬃcacy in humans, eﬀorts are being made to improve the
safety of this practise. The inclusion of killed parasites in
the inoculum and the use of adjuvants that promote rapid
immuneresponsesreducetheseverityofprimarylesionsand
accelerate wound healing during LZ [16, 22].
Research into ﬁrst-generation vaccines based on whole-
cell, killed Leishmania parasites dates back to the late 1930s,
when pioneering work by Brazilian scientists demonstrated
that killed parasites showed eﬃcacy as both therapeutic
and prophylactic vaccines [23]. Over the ensuing decades
numerous preparations of killed parasites were tested, either
alone or in combination with a variety of diﬀerent adjuvants.
Although displaying well-tolerated safety proﬁles, to date no
ﬁrst-generation vaccine using killed parasites has demon-
strated suﬃcient eﬃcacy as a prophylactic vaccine to be
used in widespread control programmes [24]. Most vaccine
studies focus on CL, and there have been no clinical trials
of ﬁrst-generation vaccines produced from VL Leishmania
species. Due to the strongly conserved genomes of the
Leishmaniaspecies,it is anticipated thathuman VLtrials will
follow any successful CL immunization program. Whether
the same vaccine can show eﬃcacy against both CL and
VL remains to be determined. Interestingly, killed parasite
vaccines using an alum-precipitated autoclaved L. major
(ALM) given with a BCG adjuvant have shown promise as
vaccines for VL and PKDL [25]. When given to patients with
persistent PKDL in combination with antimonial therapyJournal of Tropical Medicine 3
this vaccine showed enhanced cure rates and lower incidence
of relapse as compared to antimonial treatment alone [26].
Based on these initial studies, recommendations have been
put forward for expanded trials to examine the prophylactic
and therapeutic eﬀects of the alum-ALM + BCG vaccine for
PKDL and VL [27].
Evidence from experimental animal models supports
the development of ﬁrst-generation VL vaccines. Complete
soluble antigen (CSA) from an attenuated L. donovani
strain was eﬀective as both a therapeutic and prophylactic
vaccine in susceptible mice, without the use of an adjuvant
[28]. Importantly, CSA immunization was eﬀective against
both pentavalent antimony sensitive and resistant strains
of L. donovani. Vaccination with puriﬁed excreted-secreted
antigens from L. infantum promastigotes (LiESAp) fully
protected dogs from experimental challenge and induced a
long-lasting cell-mediated immunity [29].
A major advantage of ﬁrst-generation vaccines is that
they are conceptually simple and relatively easy to produce
in Leishmania endemic countries at low cost. However
standardization of vaccines derived from cultured parasites
is diﬃcult, and this has hindered commercial development
eﬀorts. The route of administration, formulation, and adju-
vantarealsoimportantconsiderationsinthedevelopmentof
whole-parasite vaccines, and optimisation is essential for the
induction of protective immune responses. The most recent
clinical trials of ﬁrst-generation vaccines have demonstrated
a good safety proﬁle but have not conferred signiﬁcant
levelsofprotection foruseas prophylacticvaccines.However
promisingresultsfromtrialsusingtherapeuticvaccinationin
combination with chemotherapy warrant further investiga-
tion.
3. Second-Generation Vaccines
The development of Second-generation vaccines for Leish-
mania has included recombinant proteins, polyproteins,
DNA vaccines, liposomal formulation, and dendritic cell
vaccine delivery systems. A variety of diﬀerent molecules
have been tested to date with varying degrees of eﬃcacy
(Table 1). In general VL vaccination studies have been
hamperedbythelackofasuitableanimalmodel.Thenatural
combination of dogs and L. infantum [30]a n dL. donovani
in golden hamsters [31] reproduces many features of human
VL. The canine model is particularly useful in evaluating
vaccinecandidatessincesuccessfulvaccinationofdogsmight
control the spread of disease to humans in endemic areas
where the dog is the reservoir of the parasite [32]. However,
both models suﬀer from lack of immunological reagents and
assays needed for the characterisation of immune responses.
Therefore, the mouse model of VL has been widely used to
assess vaccine candidates. While experimental VL infection
in mice does not fully reproduce the disease observed in
humans, mice are competent hosts for both L. donovani and
L. infantum and exhibit organ-speciﬁc pathology in the liver
and spleen. Other major advantages of the mouse model are
that it is amenable to genetic manipulation to create mutants
with speciﬁc deﬁciencies in the immune system and a wide
range of immunological reagents is available.
Only a small number of recombinant proteins have
been tested against VL in murine models. Early studies
showed that promastigote-derived membrane protein dp72
protected mice against L. donovani infection [59, 82], but
there has been no further advance on the use of this
antigen for the development of vaccines. The L. donovani
amastigote LCR1 protein containing 67-amino-acid repeats
homologous to repeats in a Trypanosoma cruzi ﬂagellar
polypeptide was tested for protection in mice. Recombinant
proteinledtopartialprotectionagainstL.infantumchallenge
[44], while immunization with BCG-LCR1 elicited better
protection [45]. Vaccine eﬃcacy was inﬂuenced by the
site of immunization with subcutaneous administration
superior to intraperitoneal inoculation [45]. Recombinant
hydrophilic acylated surface protein B1 (HASPB1), a mem-
ber of a family of proteins expressed only in metacyclic and
amastigote stages, has shown eﬃcacy in an experimental
mouse model of VL [8]. This vaccine did not require the
use of adjuvant, and protection was associated with the
inductionofantigen-speciﬁc,IFN-γ producingCD8+ Tcells,
a mechanism similar to DNA vaccination [8]. Immunization
with the L. donovani A2 cysteine proteinase delivered as
recombinant protein or as DNA also aﬀorded protection
against experimental challenge infection [60, 61]. Other
antigens tested include amastigote cysteine proteases (CPs)
[40], kinetoplastid membrane protein-11 (KMP-11) [65],
amastigote LCR1 [45], leishmanial antigen ORFF [63], and
NH36, a main component of the fucose-mannose ligand
[47].
Apart from deﬁned single molecules, multicomponent
vaccines have been shown to protect against VL in experi-
mental infection systems. Recombinant Q protein formed by
fusion of antigenic determinants from four cytoplasmic pro-
teins from L. infantum (Lip2a, Lip2b, P0, and histone H2A)
coadministered with live BCG protected 90% of immunised
dogs by enhancing parasite clearance [49]. To date, only
one multicomponent vaccine, Leish-111f, has been assessed
in clinical trials [83]. Leish-111f is a single polyprotein
composed of three molecules fused in tandem: the L. major
homologue of eukaryotic thiol-speciﬁc antioxidant (TSA),
the L. major stress-inducible protein-1 (LmSTI1), and the
L. braziliensis elongation and initiation factor (LeIF) [83].
There is some evidence that the Leish-111f vaccine can also
induce partial protection against VL in animal models [56];
however, it failed to protect dogs against infection and did
not prevent disease development in a Phase III vaccine trial
in dogs [55]. An optimized version, known as Leish-110f,
has recently demonstrated strong immunogenicity and some
protective eﬃcacy against L. infantum in mice [84]. The
Leish-111f vaccine is moving forward into clinical trials as
LeishF1 and is being trialled in combination with the MPL-
SEadjuvant.Thisadjuvantconsistsofmonophosphoryllipid
A, a potent TLR4 agonist, formulated with the antigen as
a stable emulsion. A recent small-scale clinical trial in a
L. donovani endemic area showed Leish-F1-MPL-SE was
safe and well tolerated in people with and without prior
VL exposure and induced strong antigen-speciﬁc T cell
responses [85].4 Journal of Tropical Medicine
Table 1: Vaccines against visceral leishmaniasis.
(a)
Vaccines tested against L. infantum
Antigen Source of antigen Vaccine delivery Animal model Outcome Reference
KMPII, TRYP,
LACK, and
GP63
L. infantum DNA vaccine Dog No protection Rodr´ ıguez-Cort´ es et al.,
2007 [33]
H2A, H2B, H3,
and H4 L. infantum DNA vaccine Mouse No protection Carri´ on et al., 2008 [34]
p36 LACK L. infantum DNA vaccine + protein
expressed in vaccinia virus Mouse Protection Dondji et al., 2005 [35]
p36 LACK L. infantum DNA vaccine Mouse No protection Marques-da-Silva et al.,
2005 [36]
p36 LACK L. infantum DNA vaccine Mouse Protection Gomes et al., 2007 [37]
p36 LACK L. infantum DNA vaccine + protein
expressed in vaccinia virus Dog Protection Ramiro et al., 2003 [38]
p36 LACK L. infantum DNA vaccine + protein
expressed in vaccinia virus Dog Protection Ramos et al., 2008 [39]
CPA and CPB L. infantum DNA vaccine +
recombinant protein Mouse Protection Rafati et al., 2006 [40]
CPA and CPB L. infantum DNA vaccine +
recombinant protein Dog Protection Rafati et al., 2005 [41]
CTE of CPIII L. infantum DNA vaccine +
recombinant protein Mouse No protection Rafati et al., 2008 [42]
CPC L. infantum DNA vaccine +
recombinant protein Mouse Protection Khoshgoo et al., 2008 [43]
LCR1 L. infantum Recombinant protein Mouse Partial protection Wilson, et al., 1995 [44]
LCR1 L. infantum Protein expressed in BCG Mouse Partial protection Streit et al., 2000 [45]
PapLe22 L. infantum DNA vaccine Hamster Partial protection Fragaki et al., 2001 [46]
NH36 L. donovani DNA vaccine Mouse Partial protection Aguilar-Be et al., 2005 [47]
FML L. donovani Protein Mouse Partial protection Aguilar-Be et al., 2005 [47]
FML L. donovani Protein Mouse Protection Oliveira-Freitas et al., 2006
[48]
Qp r o t e i n L. infantum
Recombinant fusion
protein of Lip2a, Lip2b, P0,
and H2A + BCG
Dog Protection Molano et al., 2003 [49]
Qp r o t e i n L. infantum
Recombinant fusion
protein of Lip2a, Lip2b, P0,
and H2A + BCG
Mouse Partial protection Parody et al., 2004 [50]
A2 L. donovani Recombinant protein Dog Partial protection Fernandes et al., 2008 [51]
A2 and NH L. donovani DNA vaccine Mouse Partial protection Zanin et al., 2007 [52]
LiESAp L. infantum Native protein Dog Protection Lemesre et al., 2005 [53]
and 2007 [54]
LiESAp L. infantum Native protein Dog Protection Bourdoiseau et al., 2009
[29]
Leish-111f L. major Recombinant polyprotein
of TSA, LmSTI1, and LeIF Dog No protection Gradoni et al., 2005 [55]
Leish-111f L. major
Recombinant polyprotein
of TSA, LmSTI1, and LeIF
formulated in MPL-SE
Dog Protection Coler et al., 2007 [56]
Leish-111f L. major
Recombinant polyprotein
of TSA, LmSTI1, and LeIF
formulated in MPL-SE
Dog Protection Trigo et al., 2010 [57]
CP: cysteine proteinase; CTE: C-terminal extension; BCG: Mycobacterium bovis bacillus Calmette-Guerin; SLA: soluble leishmanial antigens; FML: fucose-
mannose ligand; LiESAp: Leishmania infantum excreted-secreted antigen puriﬁed; LPG: lipophosphoglycan.Journal of Tropical Medicine 5
(b)
Vaccines tested against L. donovani
Antigen Source of antigen Vaccine delivery Animal model Outcome Reference
p36 LACK Multiple species DNA vaccine Mouse No protection Melby et al., 2001 [58]
dp72 L. donovani Native protein antigen Mouse Partial protection Jaﬀe et al., 1990 [59]
A2 L. donovani Recombinant protein Mouse Protection Ghosh et al., 2001 [60]
A2 L. donovani DNA vaccine Mouse Protection Ghosh et al., 2001 [61]
HASPB1 L. donovani Recombinant protein Mouse Protection Stager et al., 2000 [8]
ORFF L. donovani Recombinant protein Mouse Partial protection Tewary et al., 2004 [62]
ORFF L. donovani DNA vaccine +
recombinant protein Mouse Partial protection Tewary et al., 2005 [63]
ORFF L. donovani DNA vaccine Mouse Partial protection Sukumaran et al., 2003 [64]
KMP-11 L. donovani DNA vaccine Hamster Protection Basu et al., 2005 [65]
KMP-11 L. donovani DNA vaccine Mouse Partial protection Bhaumik et al., 2009 [66]
gp36 L. major Recombinant protein
expressed in bacilli Mouse Partial protection McSorely et al., 1997 [67]
gp36 L. donovani Native protein in cationic
liposomes Mouse Partial protection Bhowmick et al., 2008 [68]
SLA L. donovani Native proteins in cationic
liposomes Mouse Protection Bhowmick et al., 2007 [69]
SLA L. donovani Native proteins Mouse Protection Tewary et al., 2004 [70]
LD9, LD72,
LD51, LD31 L. donovani Native proteins in cationic
liposomes Mouse Protection Bhowmick and Ali, 2009
[71]
Leishmanial
antigens L. donovani Native proteins in
liposomes Mouse Protection Mazumdar et al., 2004 [72]
F14 L. donovani Recombinant protein Hamster Partial protection Bhardwaj et al., 2009 [73]
γ-GCS L. donovani DNA vaccine Mouse Partial protection Carter et al., 2007 [74]
FML L. donovani Native protein Mouse Partial protection Palanik-de-Sousa et al.,
1994 [75]
FML L. donovani Native protein Mouse Partial protection Santos et al., 1999 [76]
FML L. donovani Formulation with QuilA
saponin Dog Protection Borja-Cabrera et al., 2002
[77]
Leishmune
(FML) L. donovani Recombinant protein Dog Partial protection Saraiva et al., 2006 [78]
Leishmune
(FML) L. donovani Recombinant protein Dog Protection Nogueira et al., 2005 [79]
H2A, H2B, H3,
H4 and LACK L. donovani Multiunit DNA vaccine Dog Partial protection Saldarriaga et al., 2006 [80]
LPG L. donovani Puriﬁed glycolipid + BCG Hamster and
mouse No protection Tonui et al., 2003 [81]
CP: cysteine proteinase; CTE: C-terminal extension; BCG: Mycobacterium bovis bacillus Calmette-Guerin; SLA: soluble leishmanial antigens; FML: fucose-
mannose ligand; LiESAp: Leishmania infantum excreted-secreted antigen puriﬁed; LPG: lipophosphoglycan.
In addition to recombinant proteins, DNA has been
extensively tested as means of vaccine delivery. The induc-
tion of Th1 responses leading to strong cytotoxic T cell
immunity is a general property of DNA vaccines [86],
and a growing body of evidence implicates CD8+ Tc e l l s
in protective antileishmanial responses [87]. The PapLe22
antigen, which is recognised by T cells from VL patients [88],
was administered as a DNA vaccine and led to a marked
decrease in parasite burden in immunised hamsters [46].
However stimulation of peripheral blood mononuclear cells
from VL-infected individuals with recombinant PapLe22
induced IL-10 production [88], which is associated with VL
pathogenesis in humans [89]. The Leishmania homologue
for receptors of activated C kinase (LACK) is the most
extensively studied DNA vaccine against both cutaneous and
visceral leishmaniasis, but has shown inconsistent outcomes.
DNA vaccination with a plasmid harbouring the LACK
gene coadministered with, or without, IL-12 induced robust,
long-lasting protection against L. major challenge in mice,
which was dependent on CD8+ T cells [90–92]. In a het-
erologous system, priming with L. infantum LACK followed
by a vaccinia booster aﬀorded protection against L. major
infection [93]. The prime-boost regimen was also employed
to immunise dogs against L. infantum infection and elicited
protective responses in 60% of vaccinated animals [38], but
this positive outcome has been overshadowed by studies6 Journal of Tropical Medicine
where immunisation with LACK oﬀered no protection. In
an experimental mouse model the LACK DNA vaccine
induced strong Th1 responses, but failed to protect against
L. donovani challenge [58]. Other studies in the L. infantum
mouse model conﬁrmed that LACK DNA vaccination does
not confer protection against VL despite the presence of
Th1 responses [36] ;h o w e v e r ,as t r a t e g yu s i n gah e t e r o l o g o u s
prime-boost vaccination using DNA and vaccinia viruses
has shown some eﬃcacy [35]. The heterologous DNA-prime
protein-boost approach has also shown success for other VL
vaccine antigens such as ORFF [63] and cysteine proteinases
[94]. Heterologous prime-boost with gp63 antigen with
CpG-ODN as adjuvant provided durable protection against
L. donovani challenge in an experimental mouse model and
was associated with robust cellular immune responses [95].
Asgp63isamajorsurfaceproteinpresentonbothamastigote
andpromastigoteformsandshowsahighhomologybetween
VL species [96] it is an attractive target for further vaccine
development.
Insights into the role of the innate immune system, in
particular dendritic cells (DCs), have provided the impetus
for the use of DCs as a delivery system for Leishmania anti-
gens [97–99]. DCs loaded with L. donovani soluble extract
and expressing high levels of IL-12 induced protection in
the mouse model of VL when used as a therapeutic vaccine
[100]. Moreover, coadministration of DCs with antimonial
therapy resulted in complete clearance of parasites from the
liver and spleen, unlike DC immunisation alone which was
not able to clear the infection from these organs [101].
LiposomeformulationshavebeenadoptedasLeishmania
drug delivery systems, and liposomal Amphotericin B is the
current preferred drug treatment for VL in resource-rich set-
tings[102].Vesicledeliverysystemsarealsobeingconsidered
for VL vaccines and have been shown to adjuvant protein
antigens and induce sustained Th1 immune responses [103].
These delivery systems have shown some protection against
L. donovani infection in experimental mouse models [104]
and provide a new approach to the development of VL
vaccines.
R e c e n t l y ,P e t e r se ta l .[ 105] demonstrated that sand ﬂy
transmission of parasites abrogates vaccine-induced protec-
tive immunity. While mice vaccinated with killed parasites
were refractory to a needle challenge, they were susceptible
to the sand ﬂy inoculum implying that the protective
responsesinvaccinatedmicewereeithernotgeneratedornot
maintained. These data provide a rationale for the inclusion
of sand ﬂy saliva components, which are speciﬁc to natural
infection, in vaccine design. The sand ﬂy injects Leishmania
parasites in the presence of saliva, which contains a range
of pharmacologically active molecules that can modulate
host’s immune and inﬂammatory responses and facilitate
establishment of infection. For a number of years salivary
gland antigens have been targeted as potential candidates
for antileishmanial vaccine development, primarily against
L. major. Nevertheless, it has been shown that children who
underwent anti-VL delayed-type hypersensitivity (DTH)
conversion also had increased titers of antibodies directed
to sand ﬂy saliva suggesting that mounting an eﬀective
antileishmanial response mightbelinked toneutralizationof
saliva components [106].
4.Development of CanineVaccines
Eliminating animal reservoirs has been an essential public
health tool for the control of many zoonotic diseases, such
as rabies [107] and brucellosis [108]. Canines, particularly
domestic dogs, are the main reservoir for VL species and
are considered the main source of zoonotic transmission
to humans. The development of an eﬀective canine visceral
leishmaniasis (CVLs) vaccine represents a cost-eﬀective tool
for interrupting the transmission cycle and controlling
zoonotic VL infection in humans.
CVL is widespread throughout South America [9]a n d
theMediterranean[109]whereL.infantumisthemostsignif-
icant causative agent of disease. L. donovani is considered to
be zoonotic, but as yet there has been no clear identiﬁcation
of the reservoir host animal [110]. Asymptomatic infection
is common in dogs, and as a large reservoir of parasites
are present in the skin, asymptomatic animals are a major
source of infection for vector transmission [10]. Human VL
is an emerging disease in many areas of the world, including
Northern Europe [111]a n dN o r t hA m e r i c a[ 112], and the
spread of VL into nonendemic areas is often preceded by
increasedincidenceofcanineinfection.Thereisconcernthat
increased mobility of dogs and changes in vector habitat will
result in increased transmission of human VL in previously
nonendemic areas [113].
Treatment of CVL shows low eﬃcacy with drugs success-
fully used for human VL chemotherapy, and drug treatment
of dogs rarely results in cure [114]. Control programmes for
CVL have a demonstrated capacity to reduce the prevalence
of human VL disease following interventions that target
dog populations in endemic regions [115]. However these
public health campaigns are often complex and expensive
to maintain, leading to varying degrees of eﬃcacy. The
use of insecticide-impregnated collars can reduce the risk
of contracting CVL [116], but is costly and diﬃcult to
implement at a national level. The culling of seropositive
dogs has long been recommended in Brazil; however this
approach has not lead to a reduction in the number of
humanVLcasesandmaybeoflimitedvalue[117].Therefore
the development of vaccines against CVL is an attractive
approach to controlling infection in dogs, reducing the
parasite reservoir and thus reducing the risk of transmission
of VL to human populations.
Immunological characterisation of CVL reveals cellular
and humoral immune responses comparable to human
infection,includingimmunedysregulationandincreasedIL-
10 which is associated with disease manifestation and pro-
gression [118]. Disease resistance is associated with strong
Th1-type immune responses, including IFN-γ expression by
antigen-speciﬁc T cells. Thus, analogous to a human VL
vaccine, an eﬀective CVL vaccine needs to induce strong
and long-lasting cell-mediated immunity. Adjuvant choice
must be carefully considered for CVL interventions, as live
BCG is not appropriate for use in dogs and the identiﬁcation
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for safe and eﬀective CVL vaccines [119]. In addition,
sand ﬂy components are being considered for inclusion
in CVL vaccine. Reactive antibodies to two sand ﬂy saliva
components (LuLo-D7 and LuLo YELLOW) were identiﬁed
in infected dogs and proposed as possible vaccine candidates
against CVL [120]. Evaluation of a killed Leishmania vaccine
containing sand ﬂy saliva extract indicated that the vaccine
is highly immunogenic and provided support for further
development of saliva components as candidates for anti-
VL vaccine [121]. This is supported by vaccination studies
using the hamster VL model, showing that salivary protein
LJM19 was able to protect hamsters from fatal infection with
L. infantum [122]. In addition, immunization with salivary
proteins LJM17 and LJL143 induced strong cellular and
humoral responses in dogs and might be an advantageous
addition to anti-CVL vaccine [123].
Currently there are two commercially available CVL
vaccines, Leishmune and Leishtec, and new vaccines under
developmentincluderecombinantantigenvaccinesandboth
live and killed whole-cell vaccines.
The Leishmune vaccine was the ﬁrst commercially
licensed vaccine for CVL, produced by Fort Dodge Animal
Health and has been available in Brazil since 2004 [124].
This vaccine consists of the fucose mannose ligand (FML)
isolated from L. donovani plus a saponin adjuvant. FML is a
glycoprotein mixture, and the surface glycoconjugate GP36
is the major immunogen component [125]. This vaccine
induced a signiﬁcant and strong protective eﬀect during
phase III trials in dogs living in a VL-endemic area in
Brazil with a vaccine eﬃcacy as high as 80% [77, 126].
This protection lasted up to 3.5years following vaccination,
indicating induction of a long-lasting immunity [77]. As
Leishmune-vaccinated dogs showed a complete absence of
parasites, this renders them noninfectious and contributes to
the breakdown of the zoonotic VL transmission cycle [79].
DuringphaseIIItrialsofLeishmunetherewasaconcomitant
reduction in human VL cases in districts where dogs
were vaccinated [126] demonstrating that CVL vaccination
interrupts the transmission of disease to humans. FML
antigens are present on the surface of Leishmania parasites
throughout the life cycle, and antibodies raised in vaccinated
dogs prevented the binding of procyclic promastigotes to the
sand ﬂy midgut [78]. Thus Leishmune acts as a transmission
blocking vaccine by clearing parasites from the animal
reservoir and preventing survival of the parasite in the
sand ﬂy vector. Currently the Leishmune vaccine is used
as a prophylactic and is recommended for asymptomatic
noninfected dogs. However studies show that Leishmune
is eﬀective as a therapeutic vaccine for naturally infected
dogs [127], particularly when given in combination with
chemotherapy[128].Emergingwide-scaleﬁeldstudiesreveal
that Leishmune decreases the incidence of both human
and canine visceral leishmaniasis after dog vaccination with
Leishmune [129].
A second vaccine, known as Leish-Tec, is being com-
mercially developed by the Hertape Calier Sa´ ude Animal
and consists of adenovirus expressing the L. donovani A2
antigen. Whilst the results from phase-III trials of Leish-
Tec are yet to be published it is known that immunization
with a recombinant A2 protein elicits protection against the
onset of clinical VL in experimental dog infections [51].
The recombinant adenovirus encoding the A2 gene was
capable of inducing strong Th1-type immune responses in
vaccinated mice and reduced parasite burdens following
challenge with VL parasites [130]. Together these studies
indicate that A2 is an important candidate antigen for the
development of CVL vaccines, and future studies should
report on the impact of this intervention on both canine and
human VL infection.
As many of the clinical and immunological features
of CVL are similar to those observed in human VL,
experimental challenge in dogs represents a useful system
for evaluating the eﬃcacy of vaccine candidates. The Leish-
111f + MPL-SE vaccine is a leading vaccine candidate from
human VL and has shown therapeutic eﬃcacy in recent CVL
trials [57]. Live attenuated parasites vaccines are also being
explored in canine models, including a drug-attenuated line
of L. infantum established by culturing promastigotes under
gentamicin pressure. The attenuated L. infantum vaccine
strain did not induce clinical symptoms of VL in dogs and
provided protection from subsequent challenge with live
virulent L. infantum [131].
The elimination of human VL will be diﬃcult to
achieve in the presence of persisting animal reservoirs, and
veterinary intervention is an important tool for reducing the
global burden of human VL disease. The identiﬁcation of
measurable and reliable biomarkers of immunogenicity and
protection induced by CVL vaccines may also be informative
for human VL vaccine eﬀorts.
5.LiveAttenuatedVaccines
Historically the most successful vaccines against intracellular
pathogens have been based on live attenuated organisms.
Vaccination strategies using live attenuated Leishmania para-
sites are attractive as they closely mimic the natural course
of infection and may elicit clinically protective immune
responses. A live attenuated vaccine strain would present
a full complement of Leishmania antigens to the host
immune system along with appropriate pattern-recognition
molecules for the parasite. Live vaccines also deliver anti-
gens to the correct cellular and tissue compartments for
appropriate processing and presentation to the host immune
system.Together,thisenhancesthecapacityofliveattenuated
vaccines to promote antigen-speciﬁc eﬀector and memory
immuneresponsesthatconferlong-lastingprotectiveimmu-
nity.
The development of robust in vitro culture systems for
growth and diﬀerentiation of Leishmania promastigote and
amastigote life cycle stages has enabled the production of
attenuated vaccine strains. It should be noted that most
research in this area has utilized CL strains, such as L.
major; however the attenuation techniques are broadly
transferrable to VL causing species. It is has been known for
some time that long-term in vitro culture of promastigote
parasites leads to a loss of virulence in vivo. Studies in
experimental mouse models of CL have shown that infection
with cloned avirulent lines provides clear protection against8 Journal of Tropical Medicine
a virulent challenge infection [132]. Avirulent strains of
the VL species L. donovani and L. infantum have been
generated by repeated in vitro subculture of promastigotes
in the presence of gentamicin [133]. These drug-attenuated
p r o m a s t i g o t e sw e r ea b l et oi n v a d em a c r o p h a g e sb u tc o u l d
not survive as intracellular amastigote forms [133]. Drug-
attenuated L. infantum was avirulent in an experimental
canine model, induced strong cellular immunity produc-
tion and protection against challenge with live virulent
L. infantum [131]. Early experiments showed that γ-
irradiation rendered Leishmania parasites nonpathogenic
and infection protected against challenge in a cutaneous
Leishmania model. Protection depended on the presence of
viable irradiated parasites, suggesting that transformation
into amastigote forms is required for eﬃcacy. Interestingly
the underlying mechanism of protection may relate more
to the induction of tolerization rather than immunization
in this system [134]. Other approaches to the generation of
attenuated parasites include chemical mutagenesis screens
selectingfortemperaturesensitiveCLstrains[135]whichare
avirulent during infection and signiﬁcantly protect against
subsequent challenge.
The major concern regarding these approaches to atten-
uation is that the underlying genetic mechanisms are not
deﬁned. This creates safety concerns as the stability of
parasite attenuation is uncertain and parasites could revert
to a virulent form. Conversely, a progressive loss of virulence
may occur, resulting in parasite lines that are incapable of
establishing infection or inducing protective host responses.
A loss of parasite virulence due to long-term in vitro culture
has been demonstrated in both human patients undergoing
leishmanization and experimental mouse models [19]. Thus
in the absence of a clear genetic proﬁle, nonspeciﬁc parasite
attenuationisnotacceptableforthedevelopmentofahuman
VL vaccine.
Over the last few decades the development of a powerful
“genetic toolkit” for Leishmania species has enabled research
involving transgenic parasites [136]. L. donovani and L.
infantumparasitescanbestablytransfectedusingintegrating
expression constructs that target genes for disruption by
homologous recombination. As Leishmania organisms are
diploid throughout their lifecycle, the production of null
m u t a n t sr e q u i r e se a c ha l l e l eo fag e n et ob et a r g e t e d
individually with genetic constructs containing two diﬀerent
and independent selectable markers. The recent availability
of Leishmania genome sequences has facilitated the iden-
tiﬁcation and in-depth analysis of parasite genes crucial
for infection and virulence. Comparative genomics studies
of Leishmania species have shown a highly similar gene
content and gene order and annotation studies have revealed
only a few species-speciﬁc genes [11]. Increased knowl-
edge of potential parasite virulence factors and a greater
understanding of the antigens involved in the acquisition of
immunity have generated much interest in the development
of genetically attenuated parasite vaccines.
To date, there have been two general approaches to the
geneticattenuationofLeishmaniaparasites.First,bydeletion
of genes encoding virulence factors or the enzymes responsi-
blefortheirsynthesisandsecond,bytargetinggenesessential
for intracellular survival. Gene targeting aims to produce
parasitesthatarecapableofbeingproducedandmanipulated
in vitro, usually in promastigote form, but incapable of
sustaining virulent infection in the host, in amastigote form.
The ﬁrst genetically attenuated parasite vaccine was the L.
major dihydrofolate reductase-thymidylate synthase (dhfr-
ts) knockout, which targeted an essential metabolic gene
[137]. This null mutant was able to establish a persistent
infection in experimental mouse models, but remained
avirulent with respect to disease. Importantly vaccination
withdhfr-tsknockoutparasiteselicitedsubstantialprotective
immunity, as mice were resistant to subsequent challenge
with virulent L. major. Although further experiments in
nonhuman primate models failed to show protection these
initial studies provided proof of principle for the safety
and immunogenicity of live attenuated Leishmania vaccines
[138].Drug-sensitiveLeishmaniamutantscontainingsuicide
genes [139–141] are also being developed for use during
leishmanization, and inducible suicide mutants in L. ama-
zonensis have shown protective eﬃcacy in an experimental
hamster model [142].
To date, only a small number of studies have focused on
generating attenuated forms of the VL species L. infantum
and L. donovani as a route to the production of an attenuated
VL vaccine. One approach has targeted the transporters
for the metabolic precursors of the folate pathway, as
Leishmania parasites are auxotrophic for folate and pterin
[143]. L. donovani parasites lacking the main biopterin
transporter (BT1) showed a marked reduction in infectivity
in an experimental mouse model, and this attenuated strain
conferred protection to subsequent challenge with wild-
type L. donovani [144]. Parasites incapable of intracellular
reproduction were produced by targeting centrin, a calcium
binding cytoskeletal protein. A loss of centrin from L.
donovani parasites did not aﬀect the growth of promastigote
forms, but null mutants were unable to survive as axenic
amastigotes or in human macrophages in vitro [145]. Immu-
nization of mice and hamsters by infection with centrin
deﬁcient L. donovani protected against virulent homologous
challenge. Importantly the centrin null vaccine strain elicited
parasite-speciﬁc Th1 responses which strongly correlated
with sustained protection and also induced a level of cross
protection against L. braziliensis infection [146].
The genetic attenuation of Leishmania does not nec-
essarily require the production of null mutants. Deletion
of one allele of the L. infantum silent information regula-
tory 2 (SIR2) locus was suﬃcient to prevent amastigotes
from undergoing intracellular replication in macrophages.
Immunization with L. infantum lacking one SIR2 gene
copy elicited strong parasite-speciﬁc T cell responses and
conferred complete protection against virulent challenge in
aV Lm o u s em o d e l[ 147].
Other approaches to developing live attenuated parasites
as VL vaccines have utilised nonpathogenic Leishmania
species, an approach comparable to the use of BCG as a vac-
cine against Mycobacterium tuberculosis infection. The lizard
protozoan parasite L. tarentolae has never been found to be
associated with any human leishmaniasis and is considered
nonpathogenic. Whilst L. tarentolae is capable of infectingJournal of Tropical Medicine 9
mammalian cells and transforming into amastigotes, the
parasite does not cause clinical symptoms of disease in either
mouse or hamster models [148]. In experimental vaccine
trials L. tarentolae elicited a strong Th1-driven protective
immune response and conferred protection against infec-
tiouschallengewithL.donovaniinasusceptiblemousestrain
[149]. The use of L. tarentolae as a vaccine vector to deliver
speciﬁc Leishmania antigens in the context of a live infection
has also been explored. The L. donovani A2 antigen was
expressed in L. tarentolae, which normally lacks this protein
[150] and used as a vaccine strain in an experimental mouse
model. Vaccination protected susceptible mice against L.
infantum challenge and was associated with the production
of high levels of IFN-γ production [151].
The use of live attenuated vaccines provides a promising
vaccination strategy for VL; however safety issues regarding
the use of genetically attenuated parasites as vaccines still
need to be addressed. Many of the proposed live attenu-
ated vaccines induce long-lasting immunity to reinfection
by maintaining a low level asymptomatic infection. The
establishment of subclinical infection is particularly valuable
as the persistence of antigen is thought essential for the
generation of eﬀective memory responses to Leishmania.
However reactivation of Leishmania has been observed in
patients who are immunocompromised, such as following
HIV infection, thus the safety of attenuated parasites that
induce a subclinical infection will need to be carefully
assessed.
Transgenic parasites provide an enticing lead for vaccine
development. A continuing synergy between molecular and
immunological approaches to the development of VL vac-
cines will accelerate development of the next generation of
therapeutics. In addition, transgenic parasites are invaluable
tools for understanding host-parasite interactions [152]a n d
inform vaccine design by providing insight into immunity
and pathogenesis during VL.
6. Concluding Remarks
Preventive vaccines are recognized as the best and most cost-
eﬀective protection measure against pathogens and save mil-
lions of lives across the globe each year. Leishmania vaccine
development has proven to be a diﬃcult and challenging
task and is hampered by an inadequate knowledge of disease
pathogenesis, the complexity of immune responses needed
for protection, and the cost of vaccine development. The
burden of VL is concentrated in resource poor nations, and
a lack of political will and philanthropic investment further
aggravates the situation. However, the rise of biotechnology
industries in endemic countries, such as India, may provide
an impetus for VL vaccine development and investment. A
recent clinical trial in India assessed the safety and immuno-
genicity of the LEISH-F1+MPL-SE vaccine [85]w h i c hi s
the only Second-generation vaccine currently in clinical
development for human VL. There are currently several
new European-based VL vaccine eﬀorts including a synthetic
vaccine RAPSODI (http://www.fp7-rapsodi.eu/)[ 153], a
DNA-based LEISHDNAVAX (http://www.leishdnavax.org/)
[154], and an adenovirus vectored therapeutic vaccine (Paul
Kaye, personal communication). New adjuvants are also
being developed, and there are several clinical vaccine trials
in progress and in planning [18]. Given the rapid progress in
the ﬁelds of parasite immunology and genomics, a successful
anti-Leishmania vaccine should be achievable sooner rather
than later. There is a clear need for greater investment
in research and development to move promising vaccine
leads along the development pathway toward an eﬀective,
aﬀordable VL vaccine.
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